|
|
|
RIO Diabetes:
metformin and sulphonylurea subgroups change in weight and HbA1c
|
|
Patients in this
trial were stratified according to their oral antidiabetic medication. As a
reminder, two-thirds of patients were on a stable dose of metformin and
one-third on a stable dose of sulphonylurea.
|
|
Rimonabant was
equally effective in both strata for weight loss, with the metformin group
losing about 4.5 kg and the sulphonylurea group losing about 3.5 kg – both
findings highly significant. These findings were expected as sulphonylurea is
often associated with weight gain.
|
|
There was comparable
improvement in A1c in the rimonabant 20 mg groups, with both
showing a highly significant 0.7 point reduction.
|
|
Similar findings in
terms of significant improvement in lipid parameters, HDL-C significantly increased and
triglycerides significantly decreased were found.
|